OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) fell 14.5% on Thursday . The stock traded as low as $9.85 and last traded at $10.01, with a volume of 1,722,729 shares traded. The stock had previously closed at $11.71.

Several brokerages have weighed in on OMED. Mizuho lowered their target price on OncoMed Pharmaceuticals from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Wednesday, June 1st. Zacks Investment Research upgraded OncoMed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Jefferies Group reiterated a “buy” rating on shares of OncoMed Pharmaceuticals in a report on Sunday, May 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 target price on shares of OncoMed Pharmaceuticals in a report on Thursday, July 14th. Finally, Leerink Swann upped their price objective on OncoMed Pharmaceuticals from $11.00 to $13.00 and gave the stock a “market perform” rating in a research note on Thursday, May 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. OncoMed Pharmaceuticals has a consensus rating of “Buy” and an average price target of $19.29.

The firm has a 50 day moving average price of $12.17 and a 200 day moving average price of $11.46. The company’s market capitalization is $311.62 million.

OncoMed Pharmaceuticals (NASDAQ:OMED) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.10. The business earned $6.67 million during the quarter, compared to the consensus estimate of $8.09 million. The firm’s revenue was up 42.2% compared to the same quarter last year. During the same period last year, the business posted ($0.72) earnings per share. On average, equities analysts anticipate that OncoMed Pharmaceuticals Inc. will post ($3.39) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in OncoMed Pharmaceuticals stock. Jennison Associates LLC bought a new stake in OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 89,546 shares of the biopharmaceutical company’s stock, valued at approximately $2,018,000. Jennison Associates LLC owned 0.30% of OncoMed Pharmaceuticals at the end of the most recent reporting period.

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.